Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Fate Therapeutics ( (FATE) ) has issued an announcement.
On October 10, 2025, John D. Mendlein and Neelufar Mozaffarian resigned from Fate Therapeutics‘ Board, leading to a reduction in the Board’s size from ten to eight members. Subsequently, on October 13, 2025, Kamal Adawi was appointed as the new Chief Financial Officer, effective October 20, 2025. Adawi, with over 20 years of financial leadership experience in the life sciences industry, is expected to play a crucial role in advancing the company’s financial strategy and supporting its clinical programs, particularly the development of FT819 in systemic lupus erythematosus (SLE).
The most recent analyst rating on (FATE) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Fate Therapeutics stock, see the FATE Stock Forecast page.
Spark’s Take on FATE Stock
According to Spark, TipRanks’ AI Analyst, FATE is a Neutral.
Fate Therapeutics’ overall stock score is primarily impacted by its challenging financial performance, characterized by persistent losses and negative cash flow. While technical indicators suggest short-term bullish momentum, the negative valuation metrics due to ongoing losses and lack of dividends weigh heavily on the stock’s attractiveness. Investors should be cautious and consider the risks associated with the company’s financial instability.
To see Spark’s full report on FATE stock, click here.
More about Fate Therapeutics
Fate Therapeutics is a clinical-stage biopharmaceutical company focused on developing induced pluripotent stem cell (iPSC)-derived cellular immunotherapies. The company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. Their pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates designed to deliver multiple therapeutic mechanisms to patients.
Average Trading Volume: 1,932,288
Technical Sentiment Signal: Sell
Current Market Cap: $160.3M
See more insights into FATE stock on TipRanks’ Stock Analysis page.